{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T10:34:21Z","timestamp":1777804461490,"version":"3.51.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T00:00:00Z","timestamp":1551484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["CA123318"],"award-info":[{"award-number":["CA123318"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spirita Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10549-019-05166-3","type":"journal-article","created":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T07:41:30Z","timestamp":1551512490000},"page":"339-351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer"],"prefix":"10.1007","volume":"175","author":[{"given":"Jangsoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuicheon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon A.","family":"Fuson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra","family":"Bartholomeusz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debu","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-7275","authenticated-orcid":false,"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,2]]},"reference":[{"issue":"3","key":"5166_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/107327481001700305","volume":"17","author":"R Ismail-Khan","year":"2010","unstructured":"Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17(3):173\u2013176","journal-title":"Cancer Control"},{"key":"5166_CR2","first-page":"511","volume":"4","author":"O Brouckaert","year":"2012","unstructured":"Brouckaert O, Wildiers H, Floris G, Neven P (2012) Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 4:511\u2013520","journal-title":"Int J Womens Health"},{"issue":"15 Pt 1","key":"5166_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429\u20134434","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5166_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1517\/14728222.2011.645805","volume":"16","author":"L Santarpia","year":"2012","unstructured":"Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16(1):103\u2013119","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"5166_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A (2016) Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 8(1):48\u201356","journal-title":"Ther Adv Med Oncol"},{"key":"5166_CR6","first-page":"43","volume":"10","author":"KA Tran","year":"2016","unstructured":"Tran KA, Cheng MY, Mitra A, Ogawa H, Shi VY, Olney LP et al (2016) MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Des Dev Ther 10:43\u201352","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"5166_CR7","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1080\/03007995.2017.1349657","volume":"33","author":"Y Yang","year":"2017","unstructured":"Yang Y, Liu YH, Sun X, Yu MW, Yang L, Cheng PY et al (2017) Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. Curr Med Res Opin 33(9):1663\u20131675","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"5166_CR8","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1158\/1535-7163.MCT-15-0243","volume":"14","author":"C Bartholomeusz","year":"2015","unstructured":"Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J et al (2015) MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther 14(12):2773\u20132781","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"5166_CR9","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.7150\/jca.13266","volume":"6","author":"J Lee","year":"2015","unstructured":"Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C et al (2015) Comprehensive two- and three-dimensional RNAi screening identifies PI3K inhibition as a complement to MEK inhibitor AS703026 for combination treatment of triple-negative breast cancer. J Cancer 6(12):1306\u20131319","journal-title":"J Cancer"},{"issue":"1","key":"5166_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1124\/jpet.110.168583","volume":"335","author":"K Muramoto","year":"2010","unstructured":"Muramoto K, Goto M, Inoue Y, Ishii N, Chiba K, Kuboi Y et al (2010) E6201, a novel kinase inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther 335(1):23\u201331","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"5166_CR11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1021\/ci300135g","volume":"52","author":"M Ikemori-Kawada","year":"2012","unstructured":"Ikemori-Kawada M, Inoue A, Goto M, Wang YJ, Kawakami Y (2012) Docking simulation study and kinase selectivity of f152A1 and its analogs. J Chem Inf Model 52(8):2059\u20132068","journal-title":"J Chem Inf Model"},{"key":"5166_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1476-4598-11-75","volume":"11","author":"SA Byron","year":"2012","unstructured":"Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J et al (2012) Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 11:75","journal-title":"Mol Cancer"},{"issue":"5","key":"5166_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1124\/dmd.117.079194","volume":"46","author":"G Gampa","year":"2018","unstructured":"Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L et al (2018) Brain distribution of a novel MEK inhibitor E6201: implications in the treatment of melanoma brain metastases. Drug Metab Dispos 46(5):658\u2013666","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"5166_CR14","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-018-0099-5","volume":"118","author":"R Tibes","year":"2018","unstructured":"Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A et al (2018) Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. Br J Cancer 118(12):1580\u20131585","journal-title":"Br J Cancer"},{"issue":"6","key":"5166_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1158\/0008-5472.CAN-15-1580","volume":"76","author":"W Zhang","year":"2016","unstructured":"Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR et al (2016) The dual MEK\/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations. Cancer Res 76(6):1528\u20131537","journal-title":"Cancer Res"},{"issue":"5","key":"5166_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tcb.2004.03.011","volume":"14","author":"NO Carragher","year":"2004","unstructured":"Carragher NO, Frame MC (2004) Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 14(5):241\u2013249","journal-title":"Trends Cell Biol"},{"issue":"2","key":"5166_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1568026053507723","volume":"5","author":"EM Wallace","year":"2005","unstructured":"Wallace EM, Lyssikatos JP, Yeh T, Winkler JD, Koch K (2005) Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 5(2):215\u2013229","journal-title":"Curr Top Med Chem"},{"issue":"9","key":"5166_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4161\/cbt.10.9.13273","volume":"10","author":"C Mitchell","year":"2010","unstructured":"Mitchell C, Yacoub A, Hossein H, Martin AP, Bareford MD, Eulitt P et al (2010) Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Cancer Biol Ther 10(9):903\u2013917. https:\/\/doi.org\/10.4161\/cbt.10.9.13273","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"5166_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1158\/1541-7786.MCR-07-0080","volume":"6","author":"N Chetoui","year":"2008","unstructured":"Chetoui N, Sylla K, Gagnon-Houde JV, Alcaide-Loridan C, Charron D, Al-Daccak R et al (2008) Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6(1):42\u201352. https:\/\/doi.org\/10.1158\/1541-7786.MCR-07-0080","journal-title":"Mol Cancer Res"},{"issue":"4","key":"5166_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/leu.2011.287","volume":"26","author":"M Konopleva","year":"2012","unstructured":"Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B et al (2012) MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex. Leukemia 26(4):778\u2013787. https:\/\/doi.org\/10.1038\/leu.2011.287","journal-title":"Leukemia"},{"issue":"2","key":"5166_CR21","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1124\/mol.113.086140","volume":"84","author":"DL Hermanson","year":"2013","unstructured":"Hermanson DL, Das SG, Li Y, Xing C (2013) Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIbeta downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol 84(2):236\u2013243. https:\/\/doi.org\/10.1124\/mol.113.086140","journal-title":"Mol Pharmacol"},{"issue":"6","key":"5166_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1667\/RR13856.1","volume":"182","author":"H Wu","year":"2014","unstructured":"Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z et al (2014) Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res 182(6):618\u2013625. https:\/\/doi.org\/10.1667\/RR13856.1","journal-title":"Radiat Res"},{"issue":"12","key":"5166_CR23","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1535-7163.MCT-16-0017","volume":"15","author":"H Kawakami","year":"2016","unstructured":"Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA (2016) Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther 15(12):3015\u20133027. https:\/\/doi.org\/10.1158\/1535-7163.mct-16-0017","journal-title":"Mol Cancer Ther"},{"key":"5166_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-15-0243","author":"C Bartholomeusz","year":"2015","unstructured":"Bartholomeusz C, Xie X, Pitner MK, Kondo K, Dadbin A, Lee J et al (2015) MEK inhibitor selumetinib (AZD6244; ARRY-142886) prevents lung metastasis in a triple-negative breast cancer xenograft model. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.mct-15-0243","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"5166_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/nri3495","volume":"13","author":"JS Arthur","year":"2013","unstructured":"Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13(9):679\u2013692. https:\/\/doi.org\/10.1038\/nri3495","journal-title":"Nat Rev Immunol"},{"key":"5166_CR26","unstructured":"ClinicalTrials.gov (2019) Search of: MEK inhibitor|interventional studies|breast cancer\u2014list results\u2014ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/results?cond=breast+cancer&term=MEK+inhibitor&type=Intr&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=&sort="},{"issue":"10","key":"5166_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules22101551","volume":"22","author":"Y Cheng","year":"2017","unstructured":"Cheng Y, Tian H (2017) Current Development status of MEK inhibitors. Molecules 22(10):1551","journal-title":"Molecules"},{"issue":"15_suppl","key":"5166_CR28","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2017.35.15_suppl.1099","volume":"35","author":"J Albanell","year":"2017","unstructured":"Albanell J, Elvin JA, Ali SM, Schrock AB, Chung J, Vergilio J-A et al (2017) BRAF: an emerging target for triple-negative breast cancer. J Clin Oncol 35(15_suppl):1099\u20131099","journal-title":"J Clin Oncol"},{"issue":"5","key":"5166_CR29","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24816","volume":"116","author":"MF Rimawi","year":"2010","unstructured":"Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC et al (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116(5):1234\u20131242","journal-title":"Cancer"},{"issue":"24","key":"5166_CR30","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1158\/0008-5472.CAN-08-2755","volume":"68","author":"JH Law","year":"2008","unstructured":"Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL et al (2008) Phosphorylated insulin-like growth factor-i\/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68(24):10238\u201310246","journal-title":"Cancer Res"},{"issue":"4","key":"5166_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N","volume":"180","author":"BS Verbeek","year":"1996","unstructured":"Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JG, Hennipman A et al (1996) c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 180(4):383\u2013388","journal-title":"J Pathol"},{"issue":"12","key":"5166_CR32","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1002\/jcb.25220","volume":"116","author":"MR Maiello","year":"2015","unstructured":"Maiello MR, D\u2019Alessio A, Bevilacqua S, Gallo M, Normanno N, De Luca A (2015) EGFR and MEK blockade in triple negative breast cancer cells. J Cell Biochem 116(12):2778\u20132785","journal-title":"J Cell Biochem"},{"issue":"8","key":"5166_CR33","first-page":"1609","volume":"6","author":"K Nakai","year":"2016","unstructured":"Nakai K, Hung MC, Yamaguchi H (2016) A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res 6(8):1609\u20131623","journal-title":"Am J Cancer Res"},{"issue":"2","key":"5166_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1158\/1535-7163.MCT-11-0400","volume":"11","author":"C Bartholomeusz","year":"2012","unstructured":"Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K et al (2012) MEK1\/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 11(2):360\u2013369","journal-title":"Mol Cancer Ther"},{"issue":"60","key":"5166_CR35","doi-asserted-by":"crossref","first-page":"101452","DOI":"10.18632\/oncotarget.20843","volume":"8","author":"X Chen","year":"2017","unstructured":"Chen X, Zheng Z, Chen L, Zheng H (2017) MAPK, NFkappaB, and VEGF signaling pathways regulate breast cancer liver metastasis. Oncotarget 8(60):101452\u2013101460","journal-title":"Oncotarget"},{"key":"5166_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1533034617754024","author":"GL Shao","year":"2018","unstructured":"Shao GL, Wang MC, Fan XL, Zhong L, Ji SF, Sang G et al (2018) Correlation between Raf\/MEK\/ERK signaling pathway and clinicopathological features and prognosis for patients with breast cancer having axillary Lymph node metastasis. Technol Cancer Res Treat. https:\/\/doi.org\/10.1177\/1533034617754024","journal-title":"Technol Cancer Res Treat"},{"issue":"16","key":"5166_CR37","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-16-2622","volume":"23","author":"AM Torres-Adorno","year":"2017","unstructured":"Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, Lim B et al (2017) Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer. Clin Cancer Res 23(16):4780\u20134792","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5166_CR38","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1535-7163.MCT-11-0505","volume":"11","author":"J Jing","year":"2012","unstructured":"Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E et al (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11(3):720\u2013729","journal-title":"Mol Cancer Ther"},{"issue":"46","key":"5166_CR39","doi-asserted-by":"publisher","first-page":"80804","DOI":"10.18632\/oncotarget.20534","volume":"8","author":"TS Nagaria","year":"2017","unstructured":"Nagaria TS, Shi C, Leduc C, Hoskin V, Sikdar S, Sangrar W et al (2017) Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. Oncotarget 8(46):80804\u201380819","journal-title":"Oncotarget"},{"issue":"4","key":"5166_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.bbrc.2017.05.177","volume":"489","author":"N Sato","year":"2017","unstructured":"Sato N, Wakabayashi M, Nakatsuji M, Kashiwagura H, Shimoji N, Sakamoto S et al (2017) MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. Biochem Biophys Res Commun 489(4):484\u2013489","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5166_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS et al (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149(2):307\u2013321","journal-title":"Cell"},{"issue":"2","key":"5166_CR42","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","volume":"69","author":"OK Mirzoeva","year":"2009","unstructured":"Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R et al (2009) Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69(2):565\u2013572","journal-title":"Cancer Res"},{"issue":"13","key":"5166_CR43","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26(13):2139\u20132146","journal-title":"J Clin Oncol"},{"issue":"22","key":"5166_CR44","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","volume":"22","author":"J Rinehart","year":"2004","unstructured":"Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB et al (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22(22):4456\u20134462","journal-title":"J Clin Oncol"},{"issue":"14","key":"5166_CR45","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1158\/1078-0432.CCR-09-0317","volume":"15","author":"KP Hoeflich","year":"2009","unstructured":"Hoeflich KP, O\u2019Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15(14):4649\u20134664","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5166_CR46","doi-asserted-by":"publisher","first-page":"e105792","DOI":"10.1371\/journal.pone.0105792","volume":"9","author":"EY Leung","year":"2014","unstructured":"Leung EY, Kim JE, Askarian-Amiri M, Rewcastle GW, Finlay GJ, Baguley BC (2014) Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines. PLoS ONE 9(8):e105792","journal-title":"PLoS ONE"},{"issue":"11","key":"5166_CR47","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/neuonc\/nox052","volume":"19","author":"AED Swearingen Van","year":"2017","unstructured":"Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM et al (2017) Combined kinase inhibitors of MEK1\/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro Oncol 19(11):1481\u20131493","journal-title":"Neuro Oncol"},{"issue":"4","key":"5166_CR48","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andre T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC et al (2018) Combined BRAF, EGFR, and MEK Inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8(4):428\u2013443","journal-title":"Cancer Discov"},{"issue":"6","key":"5166_CR49","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/annonc\/mdw131","volume":"27","author":"E Gaudio","year":"2016","unstructured":"Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A et al (2016) Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Ann Oncol 27(6):1123\u20131128","journal-title":"Ann Oncol"},{"issue":"26","key":"5166_CR50","doi-asserted-by":"publisher","first-page":"39595","DOI":"10.18632\/oncotarget.9153","volume":"7","author":"MS Lee","year":"2016","unstructured":"Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F et al (2016) Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 7(26):39595\u201339608","journal-title":"Oncotarget"},{"issue":"2","key":"5166_CR51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-011-1420-7","volume":"131","author":"H Zhao","year":"2012","unstructured":"Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G et al (2012) The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models. Breast Cancer Res Treat 131(2):425\u2013436","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5166_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS et al (2014) Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 4(2):232\u2013245","journal-title":"Cancer Discov"},{"key":"5166_CR53","doi-asserted-by":"crossref","unstructured":"Brufsky A, Miles D, Zvirbule Z, Eniu A, Lopez-Miranda E, Seo JH et al (2018) Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I. Cancer Research. SABCS17-P5-21-01","DOI":"10.1158\/1538-7445.SABCS17-P5-21-01"},{"issue":"5_suppl","key":"5166_CR54","doi-asserted-by":"publisher","first-page":"TPS17","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS17","volume":"36","author":"S Chumsri","year":"2018","unstructured":"Chumsri S, Polley M-Y, Anderson SL, O\u2019Sullivan CCM, Colon-Otero G, Knutson KL et al (2018) Phase I\/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer. J Clin Oncol 36(5_suppl):TPS17\u2013TPS17","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s10549-019-05218-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000}}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05166-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05166-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T02:29:58Z","timestamp":1606616998000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05166-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5166"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05166-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10549-019-05218-8","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,2]]},"assertion":[{"value":"20 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Unfortunately in the original publication of the article, the author\u2019s funding support has been mentioned incorrectly. The correct funding statement should read as \u201cThis work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson\u2019s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.\u201dThe first affiliations was incorrect in the original article. The correct information is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Naoto T. Ueno has a research agreement with Spirita Oncology, LLC. Linda J. Paradiso and Thomas Myers are employees of Spirita Oncology, LLC. All other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Animal studies and procedures were approved by The University of Texas MD Anderson Cancer Center Animal Care and Use Committee. Protocol #: 00000968-RN02 (approval date 5\/1\/2015, expiration date 4\/22\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving in animal rights"}},{"value":"This article does not contain any studies with human participants by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving in human rights"}}]}}